公开(公告)号：US20180325884A1

公开(公告)日：2018-11-15

申请号：US16041067

申请日：2018-07-20

Applicant: CLEARSIDE BIOMEDICAL, INC.

Inventor： Vladimir ZARNITSYN ,  Samirkumar PATEL ,  Daniel WHITE ,  Glenn NORONHA ,  Brian BURKE

IPC: A61K31/4439 ,  C07K16/22 ,  A61K47/38 ,  A61K9/00 ,  A61K9/10 ,  A61K9/16 ,  A61K31/573 ,  A61M37/00 ,  A61K47/26 ,  A61K47/12 ,  A61K45/06 ,  A61K39/00

CPC classification number: A61K31/4439 ,  A61K9/0019 ,  A61K9/0048 ,  A61K9/10 ,  A61K9/16 ,  A61K31/573 ,  A61K45/06 ,  A61K47/12 ,  A61K47/26 ,  A61K47/38 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2300/00 ,  A61M37/0015 ,  A61M2037/0023 ,  A61M2037/0061 ,  C07K16/22

Abstract: Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles.

公开(公告)号：US20160206628A1

公开(公告)日：2016-07-21

申请号：US15001610

申请日：2016-01-20

Applicant: Clearside Biomedical, Inc.

Inventor： Vladimir ZARNITSYN ,  Samirkumar PATEL ,  Daniel WHITE ,  Glenn NORONHA ,  Brian BURKE

IPC: A61K31/573 ,  A61K47/12 ,  A61K47/26 ,  A61K9/00 ,  A61K47/38

CPC classification number: A61K31/4439 ,  A61K9/0019 ,  A61K9/0048 ,  A61K9/10 ,  A61K9/16 ,  A61K31/573 ,  A61K45/06 ,  A61K47/12 ,  A61K47/26 ,  A61K47/38 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2300/00 ,  A61M37/0015 ,  A61M2037/0023 ,  A61M2037/0061 ,  C07K16/22

Abstract: Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles.

公开(公告)号：US20170333416A1

公开(公告)日：2017-11-23

申请号：US15673073

申请日：2017-08-09

Applicant: CLEARSIDE BIOMEDICAL, INC.

Inventor： Vladimir ZARNITSYN ,  Samirkumar PATEL ,  Daniel WHITE ,  Glenn NORONHA ,  Brian BURKE

IPC: A61K31/4439 ,  A61K47/38 ,  A61K9/00 ,  A61K9/10 ,  A61K31/573 ,  A61M37/00 ,  A61K47/26 ,  A61K47/12 ,  A61K45/06 ,  C07K16/22 ,  A61K9/16 ,  A61K39/00

CPC classification number: A61K31/4439 ,  A61K9/0019 ,  A61K9/0048 ,  A61K9/10 ,  A61K9/16 ,  A61K31/573 ,  A61K45/06 ,  A61K47/12 ,  A61K47/26 ,  A61K47/38 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2300/00 ,  A61M37/0015 ,  A61M2037/0023 ,  A61M2037/0061 ,  C07K16/22

Abstract: Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles.

公开(公告)号：US20190290485A1

公开(公告)日：2019-09-26

申请号：US16440108

申请日：2019-06-13

Applicant: CLEARSIDE BIOMEDICAL, INC.

Inventor： Rafael Victor ANDINO ,  Thomas Edward GODFREY ,  Shelley Eckert HANCOCK ,  Samirkumar PATEL ,  Keleigh Jo STRUDTHOFF ,  Jesse YOO ,  Vladimir ZARNITSYN

IPC: A61F9/00 ,  A61K38/18 ,  A61K45/06 ,  A61K38/39 ,  A61K38/36

Abstract: Devices, methods, and kits for ocular drug delivery are described herein. In some embodiments, a method includes inserting a distal end portion of a puncture member into an eye to define a delivery passageway within the eye. The delivery passageway extends through ha sclera of the eye and a choroid of the eye. The delivery passageway is less than about 1.5 mm. The method further includes conveying a substance into a subretinal space within the eye via the distal end portion of the puncture member.

公开(公告)号：US20180028516A1

公开(公告)日：2018-02-01

申请号：US15454636

申请日：2017-03-09

Applicant: CLEARSIDE BIOMEDICAL, INC.

Inventor： Vladimir ZARNITSYN ,  Samirkumar PATEL ,  Daniel WHITE ,  Glenn NORONHA ,  Brian BURKE

IPC: A61K31/4439 ,  A61K47/26 ,  A61K9/00 ,  A61K9/10 ,  A61M37/00 ,  A61K47/38 ,  A61K47/12 ,  A61K45/06 ,  A61K31/573 ,  C07K16/22 ,  A61K9/16 ,  A61K39/00

CPC classification number: A61K31/4439 ,  A61K9/0019 ,  A61K9/0048 ,  A61K9/10 ,  A61K9/16 ,  A61K31/573 ,  A61K45/06 ,  A61K47/12 ,  A61K47/26 ,  A61K47/38 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2300/00 ,  A61M37/0015 ,  A61M2037/0023 ,  A61M2037/0061 ,  C07K16/22

Abstract: Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles.

公开(公告)号：US20210260047A1

公开(公告)日：2021-08-26

申请号：US17314272

申请日：2021-05-07

Applicant: CLEARSIDE BIOMEDICAL, INC.

Inventor： Vladimir ZARNITSYN ,  Samirkumar PATEL ,  Daniel WHITE ,  Glenn NORONHA ,  Brian BURKE

IPC: A61K31/4439 ,  A61K9/00 ,  A61K9/10 ,  A61K47/38 ,  A61K45/06 ,  C07K16/22 ,  A61K31/573 ,  A61K9/16 ,  A61M37/00 ,  A61K47/12 ,  A61K47/26

Abstract: Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles.

公开(公告)号：US20190133933A1

公开(公告)日：2019-05-09

申请号：US16097303

申请日：2017-05-01

Applicant: CLEARSIDE BIOMEDICAL, INC.

Inventor： Richard BECKMAN ,  Jesse YOO ,  Rafael Victor ANDINO ,  Glenn NORONHA ,  Samirkumar PATEL ,  Donna TARABORELLI ,  Vladimir ZARNITSYN

IPC: A61K9/00 ,  A61K47/36 ,  A61F9/00 ,  A61F9/007 ,  A61M37/00

Abstract: The current disclosure relates to formulations and methods for reducing intraocular pressure (IOP) in the eye of a subject in need thereof. The disclosure also relates to formulations and methods for reducing intraocular pressure (IOP) related to glaucoma in a subject. The methods provided include non-surgically administering a non-pharmacologically active injectable formulation to the eye of the subject by using an apparatus that is suitable for delivering the formulations. The methods provided also include placing a solid implant into the eye of the subject to create a controlled space in the suprachoroidal space (SCS) or the supraciliary space of the eye of the subject in need thereof. The present disclosure further comprises facilitating and improving the aqueous outflows in the eye through the trabecular meshwork outflow pathway and/or uveoscleral outflow pathway and thereby decreasing the intraocular pressure.

公开(公告)号：US20160213662A1

公开(公告)日：2016-07-28

申请号：US15086485

申请日：2016-03-31

Applicant: Clearside Biomedical, Inc.

Inventor： Vladimir ZARNITSYN ,  Samirkumar PATEL ,  Daniel WHITE ,  Glenn NORONHA ,  Brian BURKE

IPC: A61K31/4439 ,  A61K9/16 ,  A61K9/00

CPC classification number: A61K31/4439 ,  A61K9/0019 ,  A61K9/0048 ,  A61K9/10 ,  A61K9/16 ,  A61K31/573 ,  A61K45/06 ,  A61K47/12 ,  A61K47/26 ,  A61K47/38 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2300/00 ,  A61M37/0015 ,  A61M2037/0023 ,  A61M2037/0061 ,  C07K16/22

Abstract: Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles.

公开(公告)号：US20190307606A1

公开(公告)日：2019-10-10

申请号：US16178162

申请日：2018-11-01

Applicant: CLEARSIDE BIOMEDICAL, INC.

Inventor： Rafael Victor ANDINO ,  Thomas Edward GODFREY ,  Shelley Eckert HANCOCK ,  Samirkumar PATEL ,  Keleigh Jo MAHN ,  Jesse YOO ,  Vladimir ZARNITSYN

IPC: A61F9/00 ,  A61K9/00

Abstract: Devices, methods, and kits for ocular drug delivery are described herein. An apparatus can include a housing, an energy storage member, a barrel, and a hub. The housing contains the energy storage member. A proximal end portion of the barrel is coupled to a distal end portion of the housing. The barrel is configured to contain medicament and includes at least a portion of a piston and an elastomeric member. The piston is configured to move the elastomeric member within the barrel in response to a force produced by the energy storage member. The hub is coupled to a distal end portion of the barrel. An inner surface of the hub defines a nozzle through which the medicament flows when the elastomeric member moves within the barrel. The nozzle and the energy storage member are collectively configured to produce a fluid jet to access a target location within an eye.

公开(公告)号：US20190240208A1

公开(公告)日：2019-08-08

申请号：US16124407

申请日：2018-09-07

Applicant: CLEARSIDE BIOMEDICAL, INC.

Inventor： Vladimir ZARNITSYN ,  Samirkumar PATEL ,  Daniel WHITE ,  Glenn NORONHA ,  Brian BURKE

IPC: A61K31/4439 ,  A61K47/26 ,  A61K9/00 ,  A61K9/10 ,  A61K47/38 ,  A61K45/06 ,  A61K47/12 ,  A61M37/00 ,  A61K9/16 ,  C07K16/22 ,  A61K31/573

CPC classification number: A61K31/4439 ,  A61K9/0019 ,  A61K9/0048 ,  A61K9/10 ,  A61K9/16 ,  A61K31/573 ,  A61K45/06 ,  A61K47/12 ,  A61K47/26 ,  A61K47/38 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2300/00 ,  A61M37/0015 ,  A61M2037/0023 ,  A61M2037/0061 ,  C07K16/22

Abstract: Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles.